Table 5 Univariate analysis of the clinic characteristics associated to the positivity of mpMRI and 18F-CH PET/CT

Age, years

1.01 (0.93–1.10)

0.759

1.02 (0.93–1.12)

0.694

Preoperative PSA, ng/mL

1.05 (0.95–1.15)

0.344

0.98 (0.89–1.07)

0.630

Pathologic T stage, T3

4.24 (0.94–19.26)

0.061

2.86 (0.69–11.82)

0.146

Pathologic N stage, Nx

0.93 (0.26–3.41)

0.917

0.50 (0.13–1.86)

0.301

Pathologic Gleason score, > 7

4.62 (0.83–25.73)

0.081

13.91 (1.54–125.63)

0.019

Positive surgical margin

0.69 (0.19–2.53)

0.578

0.34 (0.09–1.30)

0.116

Perineural Invasion

1.30 (0.36–4.72)

0.691

1.02 (0.28–3.68)

0.973

 Post radical prostatectomy

20.66 (0.45–964.07

0.121

2.17 (0.71–6.63)

0.172

 On day of biochemical failure

30.90 (1.50–635.84)

0.026

2.48 (0.76–8.15)

0.135

 On day of MRI-PET/CT

1.62 (0.88–2.98)

0.122

1.64 (0.90–2.99)

0.110

 Lowest PSA level after surgery

16.77 (0.530–531.40)

0.110

2.03 (0.72–5.69)

0.180

 Radical prostatectomy and hormonotherapy or radiotherapy

1.63 (0.38–6.87)

0.509

0.67 (0.16–2.73)

0.573

 To first PSA recurrence

0.99 (0.95–1.03)

0.568

0.98 (0.94–1.01)

0.217

 To MRI-PET/CT

1.00 (0.98–1.02)

0.807

0.99 (0.97–1.01)

0.203

PSA doubling time, months

1.02 (0.92–1.12)

0.772

0.94 (0.85–1.05)

0.271